A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States.

Publication Type:

Journal Article

Source:

Cancer journal (Sudbury, Mass.), Volume 20, Issue 1, p.18-24 (2014)

Keywords:

2014, Clinical Research Division, February 2014

Abstract:

This open-label, multicenter study was designed to allow access to vemurafenib for patients with metastatic melanoma, bridging the time between end of enrollment in the phase III registration trial (December 2010) and commercial availability following US Food and Drug Administration approval of vemurafenib for the treatment of unresectable or metastatic BRAF-mutated melanoma (August 2011).